

Title (en)  
ANTI-AGE ANTIBODIES AND METHODS OF USE THEREOF

Title (de)  
ANTI-ALTERS-ANTIKÖRPER UND VERFAHREN ZU DEREN VERWENDUNG

Title (fr)  
ANTICORPS ANTI-AGE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS

Publication  
**EP 3362483 A1 20180822 (EN)**

Application  
**EP 16731696 A 20160527**

Priority

- US 201562241007 P 20151013
- US 201514974561 A 20151218
- US 2016034880 W 20160527

Abstract (en)  
[origin: WO2017065837A1] An anti-AGE antibody comprises a protein or peptide that comprises at least one amino acid sequence having at least 90% sequence identity, preferably at least 95% sequence identity, more preferably at least 98% sequence identity, with specific amino acid sequences. The anti-AGE antibody binds to a protein or peptide that exhibits a carboxymethyllysine modification. The anti-AGE antibody may be used for killing senescent cells, killing partially-functional or non-functional cells, treating sarcopenia, promoting tissue or organ regeneration, promoting regenerative processes or overcoming aging effects, treating atherosclerosis, preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, preventing or delaying the onset of lordokyphosis, treating inflammation or autoimmune disorders, treating neurodegenerative disorders or treating cancer.

IPC 8 full level  
**C07K 16/44** (2006.01); **C07K 14/47** (2006.01)

CPC (source: EP KR RU)  
**A61P 9/10** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 21/02** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/12** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 14/4738** (2013.01 - EP); **C07K 16/18** (2013.01 - EP KR RU); **C07K 16/44** (2013.01 - EP KR); **C07K 16/46** (2013.01 - RU); **A61K 2039/505** (2013.01 - EP KR); **C07K 2317/24** (2013.01 - EP KR); **C07K 2317/92** (2013.01 - EP KR)

Citation (search report)  
See references of WO 2017065837A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2017065837 A1 20170420**; AU 2016336959 A1 20180412; BR 112018007422 A2 20181030; CA 3000815 A1 20170420; CA 3000815 C 20221101; CN 108431044 A 20180821; EP 3362483 A1 20180822; IL 258397 A 20180531; JP 2018535953 A 20181206; KR 20180056689 A 20180529; MA 42979 A 20210526; MX 2018004545 A 20180801; RU 2018110885 A 20191119; RU 2018110885 A3 20200130; RU 2766209 C2 20220209

DOCDB simple family (application)  
**US 2016034880 W 20160527**; AU 2016336959 A 20160527; BR 112018007422 A 20160527; CA 3000815 A 20160527; CN 201680059997 A 20160527; EP 16731696 A 20160527; IL 25839718 A 20180327; JP 2018519727 A 20160527; KR 20187010762 A 20160527; MA 42979 A 20160527; MX 2018004545 A 20160527; RU 2018110885 A 20160527